Loading
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Previous close
$4.52
−$0.05 · -1.09%
Pre-market
$4.50
−$0.02 · -0.44%
Oct 8, 4:00 AM ET
Regular session · ET · Market data may be delayed.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Day range
Current $4.52
52-week range
Current $4.52
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
21
Expensive
Sentiment
43
Mixed
Risk
80
High Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Day range
Current $4.52
52-week range
Current $4.52
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 93K USD | 120K USD | — | — |
| Cost of goods sold | — | 50K USD | 77K USD | 452K USD | — |
| Gross profit | — | 43K USD | 43K USD | −452K USD | — |
| Research and development | 74.54M USD | 70.47M USD | 38.04M USD | 34.35M USD | 26.44M USD |
| Selling, general, and administrative | 22.28M USD | — | — | 14.58M USD | 10.49M USD |
| Operating expenses | 96.82M USD | 93.57M USD | 50.88M USD | 48.93M USD | 36.93M USD |
| Interest income | 1.54M USD | 4.15M USD | 1.26M USD | 797K USD | — |
| Interest expense | — | — | — | — | 1.44M USD |
| Depreciation and amortization | 1.13M USD | 677K USD | 286K USD | 452K USD | 676K USD |
| Operating income | −96.82M USD | −93.53M USD | −50.84M USD | −49.39M USD | −36.93M USD |
| Net income | −140.95M USD | −68.69M USD | −77.09M USD | −46.45M USD | −38.74M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
